68Ga-OncoACP3 (Imaging)

68Ga-OncoACP3 is a small molecule radiotracer with ultra high-affinity for Acid Phosphatase 3 (ACP3).

ACP3 is a phosphatase that is abundantly expressed in prostate cancer but undetectable in normal organs, with the exception of the healthy prostate. A side-by-side comparison between ACP3 and PSMA (currently considered the most validated marker of prostate cancer) has shown that ACP3 is more abundantly expressed in prostate cancer than PSMA, but cleaner in normal organs.

68Ga-OncoACP3 consists of (i) a small organic ligand targeting ACP3, (ii) an innovative spacer structure and (iii) a DOTA chelator for the incorporation of 68Gallium.

68Ga-OncoACP3 displays best-in-class performance both in vitro and in vivo with the highest reported affinity to the ACP3 antigen. In preclinical models of cancer, the product has shown a rapid and selective accumulation in the tumor mass with an extraordinarily low uptake in normal organs (including kidneys and salivary glands).

68Ga-OncoACP3 is being developed as companion diagnostic for our therapeutic OncoACP3 candidates (177Lu-OncoACP3 and 225Ac-OncoACP3). A Clinical Trial Application for a First-in-Human study with 68Ga-OncoACP3  has been submitted to regulatory authorities. 68Ga-OncoACP3 is partnered with RayzeBio, a Bristol Myers Squibb Company.

ONGOING CLINICAL TRIALS
  • OncoFAP-68Ga has recently entered in a first-in-man imaging study in patients with advanced solid cancers
  • Additional studies with OncoFAP-68Ga (Imaging) and OncoFAP-177Lu (Therapy) are about to start